#HER2 positive

[decievinglysilent]

2023

Has brought on way more health problems than I wanted to know

1. My best friend was diagnosed with HER2 positive breast cancer. She had a double mastectomy and is now facing chemo next week. She’s only 29. She has had more complications with this than should be possible. More hospital stays and procedure that should never have been done.

2. My mom had some chest pain going on and spent the night in the hospital. That was insane

3. Me. I’ve had a hell of a ride. In February, I had a UTI. Treated it and about a week later, I got another infection which led to a visit to an urologist. Before that, I had a CT done, per request of my PCP due to the possibility of kidney stones based on my symptoms at the time. CT comes back, and I have kidney stones still in my kidneys 🫠 along with nephrocalcinosis (whatever that is). So after that, I went for a follow up appointment with the urologist who said that I’ll be referred to an nephrologist because of the stones being in my kidneys (one in each kidney) and the other thing.

I see the nephrologist who is super nice and clearly knows what he’s doing based on his bio on our hospital network’s website. He also understands the importance of mental health He had me do tests, one being a 24 hour pee test (a nightmare) and then follow up. I’m also more than likely the youngest patient 🫠

At the follow up, I’m thinking I’ll just be dismissed because there’s nothing wrong and I’m better. Like what more can you do for kidney stones in your kidneys? The other thing there’s nothing to be done.

Nope.

I’m told (which he’s right on) that I need to drink more water or fluids and proceeded to prescribe me Potassium Citrate which apparently helps avoid stones. When I asked him how long I’ll be on it, he basically stated to me “lifelong” 🫠🫠🫠

So much for being discharged and I get to go back again next year while doing that same damn 24 hour pee test.

So 2023 has taught me what a nephrologist is and that cancer sucks.

#cancer #fuck cancer #HER2 positive #breast cancer #mastectomy #nephrology #nephrologist #kidneys #kidney stone #nephrocalcinosis #health #physical health

[aria-ashryver]

caesar keel over yet?

ik you sent this a couple weeks ago, but i thought it was funnier if i answered it today

IDES OF MARCH FINAL STATS!!

Diagnosis: Aggressive HER2+ ductal carcinoma, weakly estrogen positive, metastasized, technically incurable Name of Tumor: Caesar Classification: little bitch

108 IV lines / blood tests / self-administered injections

19 Eggs harvested

9 Embryos frozen

8 Supplementary medications

5 Ultrasounds

4 Computed Tomography (CT) scans

3 Mammograms

3 Chemo regime changes

2 Core biopsies

1 Positron Emission Tomography (PET-CT) scan

1 Bone Scintigraphy

1 Multigated Aquisition (MUGA) scan

1 Echocardiogram

1 Electrocardiogram (ECG)

1 round of genetic testing

1 "this is the biggest tumour I have seen in my recent years as an oncologist"

1 reclassification from Stage 2 to Stage 4

1 "this is one of the best responses to chemotherapy I have ever seen"

(and GOD KNOWS how many litres of Paclitaxel, Pertuzumab, and Trastuzumab pumping through my veins...)

We can safely call it. At my last clinic, my oncologist told me he was happy with that my last few scans had remained stable, and that I wouldn't require any surgery or radiation therapy.

Folks. I did it.

CAESAR'S ASS IS DEAD YALL I BEAT CANCER HAPPY IDES OF MARCH 🔪🔪🔪🔪🔪🔪🔪🔪

#aria pincushion tally: #FINAL SCORE #108 #cw cancer #so yes #i will technically have to continue with treatment #i need to do immune therapy every three weeks #likely for the rest of my life #and yeah they do kinda suck #but not as much as chemo so thats a win #also I MAY possibly still have surgery if I want it #not sure yet #hopefully i'll find out more on that soon #but yeah #get fucked caesar #ur a stupid ho #happy ides of march yall 😊 #ides of march

[thankyousirmayihaveanother]

I was feeling festive this year so just in time for october I picked up some stage II HER2 positive breast cancer #hotgirlshit

#it's been a minute but I figured I'd update lmfao #starting chemo next week #obligatory SGK can eat a bag of dicks tag for shira #I will not be answering questions at this time but I will see everything and I am thankful <3

[weedhorse69]

H E R 2 HIRTU POSITIVE CARCINOMA , Stage 2 Carcinoma

2 medicines -Directly for 2 carcinoma

Targeting cancer they saw

Treatment with chemotherapy and her2 directed ttmt called tchp

gifts

HAIR SERUM

book

Gloves and booties that reduce tingling in hands and feet

Suzzi pad cold therapy socks and gloves. This is the name. Sorry I forgot. 😂

#i dont wanna think about it anymore #mom #cancer

[31-with-mbc]

Day 3

Maybe it is the anxiety maybe it is the steroid in my system or maybe it is the excitement of being alive, I woke up at 5am. Early bird, you might say. I looked outside, I didn’t hear any bird singing, the only early bird this morning, you should say. 😉

No need to waste beautiful morning alone time right? I read Bible, prayed, texted my family, and just stared at my sleeping babies on Cubo app. Look at these cute chubby little cheeks! Ohh my heart. It is amazing how little things can warm up one’s heart so quickly and fully. Kids are truly blessings. Can you believe my hubby and I were literally talking about having a third baby right before going through all the scans and diagnosis? Right now that plan is on pause. But who know? Life is full of wonders and miracles. One can NEVER give up.

Experienced minor diarrhea, low energy and no appetite. I think the drugs finally hit me, or like my friend H said, they are WORKing! Pain is no longer a pain when you consider it as win. Hooray!

Got the second part of my pathology report back: ER negative PR negative and HER2 positive. What does it mean to me? What does it mean to my treatment? I do not know.

But I know, keep my chill up, keep my hope up, keep fighting!

Xoxo,

L

#my story

[nevertellmetheodds2017]

Metastatic breast cancer survival stats

I have had these notes for ages and I have shared them with people many times but so often on social groups, facebook, social media, zooms etc they’re unpopular and ignored.

Lots of people like to be in denial, pretending not to listen to reality numbers.

It’s bullshit pretending how much better things are. Here will be your quick lesson with the data. 

I will start with data from 2010-2015. Yup, not ideal, that’s 7 years out. I will update it for you but this has got to be one the best places to start so here we go. One article which will give you excellent view.

Table 3 is the place to look at. You will see it matters:

-location of metastasis 

-ER+ (estrogen) or neg

-HER2+ (human epidermal growth factor 2) or neg

-Triple Negative (TN)

Just have a look at each of the 4 squares. Pick a hormone category, look at the left up & down,  find 50% spot & go sideways across, pick whatever color chart you like, then go down to the bottom left to right sign. That will tell you at which months alive the median is falling apart. 

A median means that at a given point, 50% are dead, 50% are alive. 

(Just take a moment to pause & think this because this is the part constantly skipped on in discussions and social media. Half are dead but people pretend they’re in a full room of survivors. Way too easy to ignore and not count the dead… )

You can also look the other way. Look at the bottom left to right, find the number 60 (60 months = 5 years) and go up. Pick a color chart and go to the left when you hit it & you’ll see what percentage of that group hits 5 yr survival. All clear, right? 

(if you want to read the whole article, go crazy but honestly, the chart is all we need. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-6311-z) 

Now it’s 7 years later and even though I’ve been ill and unwell in many ways, I will post the 7 year estimate & what is changing in the past 7yrs as announced at ESMO & ASCO this spring.

That is a summary of percentage groups hitting the 5 yrs. 

Some more details if you’re really interested: 

The HER2+: is the big wow, shit is happening section. Not only is their median outsource up, there is now a whole new thing about people with quite *low* HER2+ also responding. So a big thing (but the majority of MBC does not have HER2+) Still, this will be an area of much research and investigation. 

ER2+: disappointing news about palbociclib. Still confusing a lot but the thing that is supposed to be improving turns out that overall survival median is not really moving as much as they’d hoped. Here’s a link to an article this month. https://www.biospace.com/article/pfizer-misses-the-mark-for-overall-survival-in-breast-cancer-patients/

Triple negs changes in last years - look at the chart above & now consider these additional things: 

-if BRCA positive, can have special genetic treatment meds which buy time

-PD-L1 positive can respond to some immunotherapy to buy time 

-Trodelvy responders can buy some time 

Thing is, most triple negs are not hitting these three responses and what we seem to have added in the last 7 yrs is about 12 months to a median?

There is some excitement this year about a portion of triple negs testing some positivity for HER2+ and registering an additional 10 months! Very exciting if someone can actually get the HER2+ & it appears to be adding 10 months to the chart that’s above (I’m HER2- on three different tests so far so alas, that sucks)* 

That’s about it. That’s where we’re at today. 

This is the problem with social groups: dead people are way outnumbered and they cannot post or communicate. Because they’re dead. 

There are going to always be outliers and if they’re very active participants, they seem to alter the data but it’s a giant myth. They’re outliers, they’re freaks, everyone is studying who is responding long and why and how and none of it is really an instant reward to a viewer. We know what the numbers are for the whole group, every individual can have different outcomes - including a very fast death, or a longer survival to several years. It can vary for individual but as a population, the numbers are all here. Way more dead people than buying time so don’t get sucked in by the yellow outliers as representing the group stats & ignoring that there are tons of sad deceased members.

Reality is things are still pretty shit - esp for TNBC group. 

*I have been thinking about HER2+ so much and actually expressed how much I hoped having it. To which a HER2+ person got super pissy at me being jealous about it & blocked me because talking about how much better it would be and being all obsessed about it pissed her off. WTF ? 

#metastatic breast cancer #breast cancer #triple negative breast cancer

[arrangoiz]

Oncotype Dx Provided Prognostic Information that Guided Therapy In Early Hormone Receptor Positive Breast Cancer

In women with HR+, HER2-negative early breast cancer: The 21-gene signature score provides prognostic information that is independent of clinicopathological features A high score (on a scale of 0 to 100): Indicates a higher rate of distant recurrence and is predictive of chemotherapy benefit The prospective Trial Assigning Individualized Options for Treatment (TAILORx): Showed that endocrine…

View On WordPress

[mblinternationalcorporation]

The Power of Antibody Reagents in Biomedical Applications

In the realm of biomedical research and clinical diagnostics, the significance of antibody reagents cannot be overstated. Antibodies are versatile molecules that play crucial roles in various applications, ranging from basic research to the development of diagnostic tests and targeted therapies. This article explores the profound impact of antibody reagents in advancing biomedical science and healthcare.

Understanding Antibody Reagents

Antibodies, also known as immunoglobulins, are specialized proteins produced by the immune system in response to foreign substances known as antigens. These proteins are highly specific and can recognize and bind to unique epitopes on antigens, initiating a series of immune responses. In laboratory settings, antibodies are harnessed as reagents for their ability to selectively target and bind to specific molecules of interest.

Antibodies in Basic Research

One of the primary applications of antibody reagents is in basic research. Scientists use antibodies to identify and localize proteins within cells and tissues, facilitating the study of biological processes and disease mechanisms. Techniques such as immunohistochemistry (IHC) and immunofluorescence (IF) rely on antibodies to visualize specific molecules under a microscope. By labeling antibodies with fluorescent or enzymatic markers, researchers can gain valuable insights into cellular structures and functions.

Moreover, antibodies are indispensable tools in techniques like Western blotting and enzyme-linked immunosorbent assay (ELISA), enabling the detection and quantification of proteins in complex biological samples. These assays are fundamental for characterizing biomarkers, studying protein-protein interactions, and assessing changes in gene expression.

Diagnostic Applications of Antibodies

Antibody-based diagnostics are widely employed in clinical settings for disease detection and monitoring. For instance, rapid diagnostic tests for infectious diseases often utilize antibodies to detect pathogen-specific antigens in patient samples. ELISA-based tests can identify antibodies produced by the immune system in response to infections, aiding in the diagnosis of viral or bacterial diseases.

Antibodies are also pivotal in medical imaging techniques like positron emission tomography (PET) and single-photon emission computed tomography (SPECT). In these methods, radiolabeled antibodies selectively bind to tumor cells or other diseased tissues, allowing for non-invasive visualization and localization of pathological sites within the body.

Therapeutic Potential of Antibody Reagents

The therapeutic landscape has been revolutionized by the development of monoclonal antibody therapies. Monoclonal antibodies, derived from a single clone of cells, are engineered to target specific antigens involved in diseases like cancer, autoimmune disorders, and inflammatory conditions. These antibodies can block harmful pathways, enhance immune responses against tumors, or deliver therapeutic payloads directly to affected cells.

Examples of successful monoclonal antibody therapies include trastuzumab for HER2-positive breast cancer and rituximab for B-cell lymphomas. The precision and efficacy of these therapies highlight the therapeutic potential of antibody reagents in personalized medicine.

Challenges and Future Directions

Despite their remarkable utility, antibody reagents face challenges such as batch-to-batch variability, stability issues, and the potential for immunogenicity. Researchers are actively addressing these issues through advanced techniques in antibody engineering and production.

The future of antibody reagents lies in developing novel formats and improving their specificity and affinity. Emerging technologies like bispecific antibodies, antibody-drug conjugates, and antibody fragments hold promise for enhancing therapeutic outcomes and expanding the scope of antibody-based applications.

Conclusion

In conclusion, antibody reagents represent a cornerstone of modern biomedical research and healthcare. From elucidating molecular pathways in basic science to enabling precise diagnostics and targeted therapies, antibodies continue to drive innovation and impact patient outcomes. As technology advances and our understanding of antibody biology deepens, the potential of antibody reagents in biomedical applications is poised to grow exponentially, ushering in a new era of personalized medicine and transformative therapies.

Through their versatility, specificity, and therapeutic potential, antibody reagents stand as testament to the enduring power of immunological tools in improving human health and combating disease.

[intriguingpeoplebyangelafloyd]

DENISE SCOTT

DENISE SCOTT

24 April 1955

Australian comedian

Denise Scott is a stand-up comedian, actress, television and radio host.

            Scott has appeared in: Malcolm (1985), Let the Blood Run Free (1992), Full Frontal (1993-1995), Neighbours (1996), Judith Lucy’s Spiritual Journey (2011), Travel Guides (2017-2019, Narrator), Tonight Live with Steve Vizard (1990), Rove Live (2001-2004), Australian Idol (2004), The Glass House (2016), Hughesy, We Have a Problem (2018-2021), Dancing With the Stars (2019), Play School (2020), Who Do You Think You Are? (2020), The Dog House Australia (2022).

            Denise Scott was born in Melbourne, Victoria, Australia and is married and has two children.

            Scott was diagnosed with aggressive form of breast cancer (HER2-positive) just before production of Mother and Son, and underwent chemotherapy whilst shooting. Mother and Son was a comedy sitcom starring Ruth Cracknell and Garry McDonald, which ran from 1984-1994. Scott renewed Ruth Cracknell’s character, Maggie Beare and said ‘I really enjoyed making her mine’. Comedian Matt Okine, her co-worker chose Scott for the role when he first had the idea of rebooting the TV program. He had previously been on an overseas stand-up comedy tour with Scott when the two hit it off. Mother and Son is about a man, aged in his 30s who moves back in with his meddling mother who suffers from dementia.

#denisescott #motherandson

#denise scott #denisescott #mother and son

[bhushans]

Global Breast Cancer Drug market: A Deep Dive into Key Drivers and Trends

The global Breast Cancer Drug market. According to a recent analysis, the market size is projected to be worth US$ 10,733.1 million in 2023. Between 2023 and 2033, the total demand for breast cancer medications is expected to expand at a Compound Annual Growth Rate (CAGR) of 1.1%, reaching approximately US$ 12,012.1 million by that time.

Breast cancer remains a significant healthcare challenge globally, with the disease's rising prevalence driving the demand for innovative treatments. Effective care of breast cancer necessitates early diagnosis and access to advanced therapies, highlighting the importance of continued innovation and development in the breast cancer drug market.

Inform Decisions With a Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-1246

Addressing Breast Cancer: A Market Focused on Innovation and Early Detection

The global breast cancer drug market is experiencing steady growth, driven by the continuous need for effective treatment options and the ongoing battle against this prevalent disease. Early detection remains a critical factor in managing breast cancer effectively.

Multiple Factors Shape Market Landscape:

Although growth is projected to be modest, several factors are influencing the breast cancer drug market:

Rising Prevalence: Unfortunately, the number of breast cancer diagnoses is expected to continue rising globally. This creates a larger patient population in need of treatment.

Novel Therapies: The development of innovative therapies, such as targeted drugs and immunotherapies, offers new treatment options and hope for improved patient outcomes.

Focus on Early Detection: Increased awareness campaigns and improved diagnostic tools contribute to earlier detection, allowing for more effective treatment interventions.

Key Takeaways:

The global breast cancer drug market is projected to reach US$12,012.1 million by 2033, reflecting a rise from US$10,733.1 million in 2023.

This growth is expected at a moderate compound annual growth rate (CAGR) of 1.1% throughout the forecast period.

The rising prevalence of breast cancer and the development of novel therapies are key drivers for market expansion.

Competitive Landscape:

In August 2021, Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash.

In June 2022, Novartis announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer.

Key Companies Profiled:

F. Hoffmann-La Roche Ltd

Pfizer Inc.

AstraZeneca

Novartis International AG

Achieve Life Science

Bristol-Myers Squibb

Eisai Co. Ltd

AbbVie

Eli Lilly & Company

Celgene Corporation

Merck & Co.

Amgen Plc.

Celldex Therapeutics

Biocon Genzyme Corporation

Key Segments Covered in the Breast Cancer Drug Industry Analysis:

By Drug Class:

SERM (Selective Estrogen-Receptor Modulators)-based

Aromatase Inhibitors-based

Biologic Response Modifiers-based

Other Hormonal Therapies-based

By Distribution Channel:

Hospital Pharmacies

Pharmacies

Drug Stores

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East & Africa

#Breast Cancer Drug

[aria-ashryver]

hey aria how u holding up ? 🙏🏼🩷

hiya love! ty ty for asking, im good! every single doctor i have seen has told me im handling things really well

(highkey taking this as permission to ramble about having cancer, so more under the jump haha)

im happy but ✨tired✨ though holy shit, look at this

between the blood tests, IV lines, and hormone injections for fertility treatments, ive had 28 injections so far this month.

twenty eight.

so. far. 😑

ngl my arms are a mess, even my bruises have bruises lmao

But! Someone took a scan of my entire skeleton last week so that was pretty metal.

I have a surgery tomorrow (for embryo freezing), and few more appointments still to go (MRIs and stuff), but im starting chemo suuuuper soon!! Can't fucking wait to be the weird egg sitting in the chemo ward for hours at a time writing vampire smut on their janky laptop 💪

Also, also!! my oncologist is the FUNKIEST LITTLE DUDE i adore him 🥹 he's really doing everything he can to make sure i am getting the best possible treatment.

💖💖💖💖💖💖💖💖💖💖💖💖

So, I have a super aggressive cancer type, right? Caesar is growing rapidly like the little attention-seeking slut he is, but the cool thing about HER2 positive type cancers is they are also super responsive to treatment, and there have been a lot of recent drug trials to specifically target the HER2 receptor - so i have a really good chance of making a complete recovery.

One such drug has recently finished trials, and is available in NZ at the moment, but only privately. It isn't publicly funded yet - if i wanted it, i'd be paying several thousand $$ per chemo cycle (and given that i just graduated uni and im having almost 20 cycles of chemo, my answer to "are you interested?" was "HAHAHAHAHA no im broke but thanks.")

WELL. My fucking oncologist comes busting into the room like the silly little lad he is going "HA! I THOUGHT OF A LOOPHOLE!!!" and he goes on to tell me about a grey area in the wording. This drug isn't available for free *unless* the patient's tumor is inoperable. And Caesar, needy bitch that he is, is a fucking massive tumor already. At this point in time, *technically*, the surgeons couldn't safely operate on me and guarantee they'd removed all my cancer. (Like, chemo will shrink Caesars lame ass so i can have surgery eventually, but right now, major surgery is a no go)

So my doctor is going to try and pull a sneaky little manoeuver he likes to call "we gonna try bend the rules a little. Not break, just bend. Shh." 🙊😈

(his exact words lmao)

So, no promises, but he's gonna try get a fancy schmancy brand-new drug included in my chemo treatment.

I know chemo is gonna suck ass, but im looking forward to getting started. And my mama is flying up here soon 😊 and all my doctors are really nice. And my neighbours cat visited me today for cuddles. And I watched the sunrise this morning and it was pretty.

I have so much to live for, you know? And so much to be happy about. This ask ran the fuck away from me lmao, but its nice to sit back and think about things.

I'm tired. But I'm happy 🌻

#aria is coming for caesars kneecaps watch this space

[trinitydigest]

HER2-Positive Gastric Cancer Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Pfizer, Hanmi Pharma, Bristol-Myers Squibb, Merck Sharp & Dohme

http://dlvr.it/T5HRsq

[newsheadlinesnow]

HER2-Positive Gastric Cancer Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Pfizer, Hanmi Pharma, Bristol-Myers Squibb, Merck Sharp & Dohme

http://dlvr.it/T5HB2f

[31-with-mbc]

31 with MBC

For those who don't know what MBC stands for - metastatic breast cancer, stage IV breast cancer. Yes, I am only 31 and yes, I am diagnosed with metastatic breast cancer. And yes, I am upset angry, and lost. But, it is reality. It is not a dream and I can't wake up from it.

I have two beautiful children, one wonderful husband, a loving mother, and a sister. Yet, I am here, not knowing if I am able to see my kids grow up, get white hair with my husband, and help my mom to get dressed when she is too old to do so. So, I am upset, because I do not know if I am able to be there for them. But I know I am loved, so much.

Long story short, found the lump while breastfeeding my newborn, biopsy confirmed it was stage 0 breast cancer on March 27th. Got double mastectomy on May 2nd. Pathology report came back with HER2 Positive. After a long month checkups and scans. I got mediport placement and lymph nodes biopsy. Pathology report came back positive. At that point I was stage 2 breast cancer patient. After another month of checkups and scans, I was told on June 29th, yesterday, I am now a stage 4 breast cancer patient because they found breast cancer cells in my liver. And tomorrow, I finally can start my first chemo treatment.

My world broke down, my heart shattered, my tears couldnt stop running. But I am here, sitting in front of the computer, I want to stay strong, stay positive, for myself, for my kids, for my family. I don't want to give up because I am still young, I should have bright years ahead of me. I want to scream, I want to run, I want to...

I want to share my story my journey. Maybe it is HIS plan all along. HE is testing me. and I shall prove myself. I shall be a better person, I shall be strong.

XOXO,

L

#metastatic breast cancer #stage iv cancer #my story

[arrangoiz]

Treatment of Hot Flashes in Women Taking Tamoxifen for Breast Cancer

Tamoxifen: Is indicated for premenopausal patients: With node-negative, hormone receptor positive, HER2-negative breast cancer: With low-risk recurrence scores (Oncotype Dx) Is a selective estrogen receptor modulator (SERM) with antiestrogenic activity in breast tissue: Reducing epithelial cell proliferation Hot flashes are one of the most common and bothersome side effects of…

View On WordPress